COVID-19 Announcements

HURON information on - Agency Response to OMB Guidance

Please read the following information from HURON on Federal Agency proposal deadlines, NCEs, closeouts and other reporting, prior approval requirement waivers, and award expenditure flexibilites. To read, please click here>>.

Update NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19)

Please read the Updated NIH (NOT-OD-20-091)  Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19). For more information, please click here>>.

 Department of the Air Force Memorandum for all Grantees- Guidance for COVID-19 No Cost Extensions

In the spirit of partnership, the Air Force Office of Scientific Research (AFOSR) is taking this opportunity to use 2CFR 200.308 to the maximum extent practicable to mitigate impacts to basic research. To read the memorandum, please click here>>.

Managing Federal Contract Performance Issues Associated with the Novel Coronavirus (COVID-19)

The Office of Management and Budget (OMB) released a memorandum that identifies steps to help ensure this safety while maintaining continued contract performance in support of agency missions, wherever possible and consistent with the precautions issued by the Centers for Disease Control and Prevention (CDC). To read the memorandum, please click here>>.

Administrative Relief for Recipients and Applicants of Federal Financial Assistance Directly Impacted by the Novel Coronavirus (COVID-19) due to Loss of Operations

The Office of Management and Budget (OMB) released a memorandum that provides similar administrative relief listed in M-20-11 to an expanded scope of recipients affected by the loss of operational capacity and increased costs due to the COVID-19 crisis. For more information, click here>>.

DOD Issues FAQs for Proposers and Awardees Impacted by COVID-19

The Department of Defense (DOD)  has issued “Frequently Asked Questions for DOD Research Proposers and Awardees Impacted by the Novel Coronavirus (COVID-19).” For more information, click here>>.

NSF Response to Coronavirus (COVID-19) Pandemic

Here is some information which the National Science Foundation has put out regarding their response to the Corona Virus (COVID-19) Pandemic. For more information, click here>>. 

Guidance for NIH-Funded Clinical Trials and Human Subjects Studies Affected by COVID-19 - NOT-OD-20-087

IBISResearch Training Being Conducted Via Virtual Instruction

In light of the rapidly evolving situation with coronavirus (COVID-19), all IBISResearch training will be conducted via remote learning until otherwise noted. For more information, click here>>.

National Science Foundation (NSF) DEVELOPS NEW WEBSITE FOR GUIDANCE ON COVID-19

NSF has developed a new website for the research community with detailed guidance on the
Coronavirus (COVID-19). For more information, click here>>.

NIH Notice on Late Application Submissions and FAQ’s Related to COVID-19

Please read the NIH notice  on Late Application submissions and FAQ’s related to COVID-19. For more information, click here>>.

ORA Readiness for Research Continuity Regarding COVID-19

The Office of Research Administration (ORA)
is proactively addressing how to best serve your needs for contract and grant administration, as COVID-19 continues to rapidly evolve. For more information, click here>>.

National Science Foundation (NSF) Notice on Operations

NSF is: Pausing non-essential travel by staff; Moving to wholly virtual merit review panels and; Encouraging NSF-sponsored meetings, to be held virtually with full implementation by the week
of March 16th.  Proposals will continue to be accepted unless announced otherwise. For more information, click here>>.

OMB Admin Relief for Recipients Directly Impacted by COVID-19

Please read the full OMB Guidance for exceptions for the grant processes as listed ONLY to the class of awards pertaining to the continued research and services necessary to carry out the emergency response related to COVID-19. For more information, click here>>.